tert-Butyl 4-(bicyclo[1.1.1]pentan-1-yl)piperazine-1-carboxylate

Catalog No. :
ACESDU613
CAS No. :
2680534-60-3
Molecular Formula :
C14H24N2O2
Molecular Weight :
252.36

IUPAC Name:tert-butyl 4-(bicyclo[1.1.1]pentan-1-yl)piperazine-1-carboxylate

tert-Butyl 4-(bicyclo[1.1.1]pentan-1-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$468.00Login to see priceInquiryInquiry
100mg95%$690.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(bicyclo[1.1.1]pentan-1-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(bicyclo[1.1.1]pentan-1-yl)piperazine-1-carboxylate
MDL No.MFCD34186683
Molecular FormulaC14H24N2O2
Molecular Weight252.36
SMILESO=C(N1CCN(C2(C3)CC3C2)CC1)OC(C)(C)C
InChI KeyLPEZLYPDECBKAJ-UHFFFAOYSA-N
Synonymtert-butyl 4-{bicyclo[1.1.1]pentan-1-yl}piperazine-1-carboxyl ate;1-Piperazinecarboxylic acid, 4-bicyclo[1.1.1]pent-1-yl-, 1,1-dimethylethyl ester
CAS No.2680534-60-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACESDU613 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACESDU613 route product structure diagram
    ACESDU6132680534-60-3
Inquiry

2. ACESDU613 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACESDU613 route product structure diagram
    ACESDU6132680534-60-3
Inquiry

Comments (0)